EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Bernhard Korbmacher
Emmeran Gams
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sunderdiek, U.
Right arrow Articles by Schipke, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sunderdiek, U.
Right arrow Articles by Schipke, J. D.

Eur J Cardiothorac Surg 2000;18:83-89
© 2000 Elsevier Science NL


Myocardial efficiency in stunned myocardium. Comparison of Ca2+-sensitization and PDE III-inhibition on energy consumption

Ulrich Sunderdieka, Bernhard Korbmachera, Emmeran Gamsa, Jochen D. Schipkeb

a Department of Thoracic and Cardiovascular Surgery, Heinrich-Heine University, Moorenstrasse 5, 40225 Düsseldorf, Germany
b Research Group of Experimental Surgery, Heinrich-Heine University, 40225 Düsseldorf, Germany

Received 7 September 1999; received in revised form 14 February 2000; accepted 21 February 2000.

Corresponding author. Tel.: +49-211-811-8331; fax: +49-211-811-8333
e-mail: usunderdiek{at}aol.com


    Abstract
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
Objective: In stunned myocardium oxygen consumption is relatively high compared with the reduced ventricular function. On the other hand, inotropic stimulation is frequently required to improve postischemic ventricular dysfunction. However, inotropic agents which act via intracellular increased calcium result in a higher oxygen demand. Therefore Ca2+-sensitization might be a favorable alternative. Methods: The effects of a novel Ca2+-sensitizer (EMD 60263, 10 µM, group 1) were compared with a phosphodiesterase (PDE) III-inhibitor (enoximon, 20 µM, group 2) on 14 isolated, blood-perfused rabbit hearts during reperfusion after a global ischemia of 20 min. Ventricular function, the pressure–volume area (PVA, a measure of total mechanical work), and total myocardial oxygen consumption (MVO2) were assessed. Contractile efficiency (EFcont), derived from the reciprocal of the slope of the MVO2–PVA relation, and external efficiency (EFex, stroke work/MVO2), were calculated. Results: At matched heart rate (group 1: 141±10 min-1 group 2: 151±28 min-1) and end-diastolic volume (1.3±0.2 ml) systolic variables were significantly decreased in stunned myocardium: LVPmax to 57±13% of control value in group 1 and to 76±7% in group 2, aortic flow to 20±4 vs. 25±8%. PVA was decreased to 57±13 and 67±11%, MVO2 was non-significantly decreased to 73±22 and 88±14%. After administration of either inotropic agent LVPmax was significantly improved to 96±12 vs. 90±8% compared with preischemic levels, aortic flow to 103±24 vs. 88±9%, and PVA 99±11 vs. 89±16%, respectively. EMD 60263 increased MVO2 to control levels (107±9%), and enoximon raised MVO2 even more significantly above control (139±13%). Both myocardial efficiency indices were significantly diminished during reperfusion: EFex to 14±9 vs. 23±7% and EFcont to 71±7 vs. 65±9% compared with preischemic levels. EFex (109±21%) was significantly, but EFcont only slightly (84±11%) increased after administration of EMD 60263, whereas EFex (57±13%) and EFcont (71±12%) remained depressed after enoximon. Conclusions: In stunned myocardium, the decreased efficiency indices show that energy utilization is disturbed. Both agents recruited an inotropic reserve, whereas Ca2+-sensitization seemed to be more favorable in terms of myocardial efficiency indices. These results indicate that alteration of myocardial calcium sensitivity contributes a major part to postischemic dysfunction. Therefore, Ca2+-sensitization may potentially be a superior method for inotropic support in the postischemic heart.

Key Words: Myocardial stunning • Efficiency, Ca2+-sensitivity • Inotropic stimulation • Thiadiazinone derivative • Isolated heart


    1. Introduction
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
After brief episodes of ischemia, myocardial function remains depressed for hours or even days. The phenomenon of myocardial stunning is characterized by impairment of contractile function, despite almost complete integrity of the myocardium and restoration of normal or near normal coronary blood flow, i.e. oxygen supply [1]. Myocardial oxygen consumption is reported to be relatively high compared with postischemic function, supporting evidence that energy utilization is disturbed [2,3].

However, while baseline ventricular function is depressed, inotropic stimulation is often required in the clinical setting. Stunned myocardium retains the capacity to respond to various inotropic interventions [6]. Via activation of ß-adrenoceptors or selective inhibition of phosphodiesterase isoenzymes, inotropic stimulation can be achieved by increasing the amount of intracellular calcium, cycled with each beat [4,7]. Thus, this pathway is accompanied with higher energy demand, whereas the energy supply is often limited in stunned myocardium. Newer inotropic agents which act by altering myofilament calcium sensitivity without increasing intracellular calcium levels might achieve an inotropic action with smaller increases of energy demand [5]. The purpose of this study was to evaluate the consequences of inotropic stimulation on myocardial energetics in stunned myocardium. We investigated the effects of a phosphodiesterase inhibitor (enoximon) and a novel calcium sensitizer (EMD 60263), a thiadiazinone derivative, on myocardial efficiency in isolated rabbit hearts.


    2. Materials and methods
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
2.1. Experimental preparation
The experiments were performed on a total of 14 male New Zealand White rabbits with an average age of 6 months and an average weight of 2200±200 g; the rabbits were handled according to the animal welfare regulations of the German federal authorities. After rapid excision, the hearts were connected to a modified Langendorff setting and perfused with a modified, erythrocytes enriched Krebs–Henseleit solution containing (in mM): NaCl 119, NaHCO3 25, KCl 4.7, CaCl2 1.8, MgCl2 1.2, EDTA 0.5 and glucose 11. The buffer was equilibrated with 72% N2, 22% O2, 6% CO2 at 37°C, giving a pH of 7.4. Bovine erythrocytes were added to achieve a hemoglobin concentration of 10 g/100 ml. The solution contained 4 g/100 ml albumin, and the Ca2+concentration was adjusted to 2.5 mM.

A water-filled latex balloon was inserted into the left ventricular cavity via the left atrium. The balloon was connected to a ‘systemic’ circuit that contained two artificial valves and a windkessel. The aortic flow was measured via an ultrasonic flowprobe (T 206, Transonic Systems), aortic pressure (=afterload) with a pressure transducer (P 23 II, Statham). The circuit permitted changes in afterload and in preload conditions without alteration of coronary perfusion pressure. A 3-F microtip manometer (SPR-249, Millar), inserted into the balloon, was used to measure left ventricular pressure. For measurement of left ventricular dimensions, sonomicrometry was employed (system 6, Triton) using two ultrasonic crystals, glued to either side of the balloon. Different balloon sizes were used depending on the heart size.

Total coronary blood flow (CBF) was drained and measured with a second ultrasonic flow-probe. The difference in arteriovenous O2 content (avD-O2) was continuously measured using absorption spectrophotometry (AVOX systems). Arterial and venous samples of the perfusion medium were measured by a Lex-O2-Con analyzer to control arterial equilibration and coronary venous measurements.

2.2. Experimental protocol
Control conditions were recorded after stabilization of left ventricular function, i.e. 20 min after the end of the instrumentation. The hearts were pseudo-randomized into two groups. The hearts of each group (n=7) were subjected to a period of 20 min normothermic, no-flow ischemia. After 30 min reperfusion, data were recorded again, and finally the inotropic agents were administered. In group 1, the calcium-sensitizer EMD 60263 with a concentration of 10 µM was added. In group 2, the phosphodiesterase inhibitor III enoximon at a concentration of 20 µM was used.

During control and reperfusion, coronary arterial pressure was held constant at 80±2 mmHg. All variables were measured at a constant temperature of 37.0±0.5°C maintained by immersing the hearts in a temperature-controlled chamber. For baseline measurements left ventricular preload, estimated via the intraventricular diameter, was maintained constant as well. The hearts were weighed at the end of the protocol.

In order to assess the end-systolic pressure–volume relationship (Fig. 1) , five to seven increasing preloading conditions were chosen by stepwise lifting the preload reservoir. Data were recorded after stabilization at each particular preload, and the data were acquired during control, after 30 min reperfusion and after administration of the inotropic agents.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1. The end-systolic pressure–volume relationship (ESPVR) was constructed by linear fitting of five to seven pairs of end-systolic pressures and volumes that were obtained by preload variation (panel A). The pressure–volume are (PVA) was assessed from the area enclosed by the systolic portion of the pressure–volume (PV) loop, the ESPVR and the end-diastolic pressure volume relation (EDPVR). Five to seven MVO2 and PVA pairs were linearly fitted for construction of the MVO2–PVA relationship (panel B). The MVO2-intercept of this relationship is identical to the MVO2 of the unloaded contraction.

 
2.3. Data acquisition
The following variables were continuously registered on a forced-ink chart recorder (Type 481, Brush): aortic flow, coronary flow, left ventricular (LV) pressure and inner diameter. Heart rate and LV dP/dt were derived from the pressure signal. At steady-state conditions after preload alteration, the variables were simultaneously stored digitally for later analysis at a sampling rate of 300 Hz.

2.4. Calculations and statistics
Hemodynamic data were computer-assisted analyzed with six to eight consecutive beats being averaged. The end-systolic pressure–volume relationship and the pressure–volume areas were calculated with the help of the computer program EASYDAT [8]. Coronary blood flow was normalized to 100 g wet weight. Myocardial oxygen consumption was calculated according to the Fick principle from normalized coronary blood flow and the difference in oxygen content of arterial and coronary venous perfusion medium.

The contractile efficiency (EFcont) was determined as the inverse slope of the MVO2-pressure–volume area relationship (Fig. 1), and the MVO2 for the unloaded contraction was assessed as the intercept of the MVO2-pressure–volume area relationship with the MVO2 axis. As an index of external efficiency (EFex), the ratio of stroke work and myocardial oxygen consumption was determined at the same inner diameters, i.e. same preload. The stroke work in turn was calculated from the peak ventricular pressure and stroke volume.

Data are expressed as mean±SD. Statistical analysis was performed with a statistical software package (Systat). Nonischemic and postischemic data were compared by paired t-testing. Analysis of variance (ANOVA) for repeated measurements was used to test differences in hemodynamic variables within any given group. When a significant overall effect was detected, a post hoc test with Bonferroni correction was performed to compare single mean values. A P value of less than 0.05 was considered indicative of a significant difference.


    3. Results
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
Compared with control, all systolic global variables were significantly depressed in the postischemic reperfused hearts. Aortic flow was decreased in group 1 to 20±4% and in group 2 to 25±8% compared with preischemic levels, LVPmax to 57±13 vs. 76±7%, and dP/dtmax to 56±12 (group 1) and 77±9% (group 2) (Fig. 2) .



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2. Effects of 20 min global no-flow ischemia and administration of inotropic agents ({square}, EMD 60263; {blacksquare}, enoximon) on aortic flow (AoF; A), peak left ventricular pressure (LVPmax; B), dP/dtmax (C) and dP/dtmin (D). Note that all variables were significantly depressed during reperfusion (Rep) and were significantly increased after administration of the inotropic agent. The bars represent mean values±SD, P<0.05, *control vs. reperfusion,°reperfusion vs. agent.

 
Early relaxation, as measured in terms of dP/dtmin, was impaired by 33±9 and 29±9%, whereas the end-diastolic left ventricular pressure remained essentially unchanged (8±3 vs. 7±3 mmHg in group 1 and 9±2 vs. 7±3 mmHg in group 2) (Fig. 2). Heart rate was similar in both groups during pre- and postischemic intervals (Fig. 3B) . The decrease of coronary blood flow was not significant in both groups. Total oxygen consumption was slightly decreased by 27±17% in group 1 and by 11±8% in group 2 (Fig. 3C). In contrast, the pressure–volume area was significantly decreased by 43±16 and 33±22% (Fig. 3A). Oxygen consumption for the unloaded contraction was not significantly changed during reperfusion (by 12±5% in group 1 and by 8±6% in group 2) (Fig. 3D).



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3. Effects of 20 min global no-flow ischemia and administration of inotropic agents ({square}, EMD 60263; {blacksquare}, enoximon) on the pressure–volume area (PVA; A), heart rate (HR; B), total myocardial oxygen consumption (MVO2; C) and the MVO2 for the unloaded contraction (MVO2unl; D). The bars represent mean values±SD, P<0.05, *control vs. reperfusion,°reperfusion vs. agent.

 
After administration of either agent, ventricular function was significantly improved. Aortic flow, LVPmax, dP/dtmax and dP/dtmin were improved to almost control levels in both groups, whereas PVA was more improved by the calcium sensitizer (to 99±17% of control) compared with enoximon (to 89±13% of control value). Enoximon increased heart rate significantly by 30±9% compared with control. In contrast, EMD 60263 reduced heart rate (13±13%), without reaching significance. Analyzing the cardiac rhythm from the left ventricular pressure signal showed that application of either inotropic agent did not result in an increased occurrence of arrhythmias. Myocardial oxygen consumption was slightly increased above control with EMD 60263 (107±9%), but enoximon raised MVO2 significantly to 139±13% compared with control levels.

Both efficiency indices were significantly diminished during reperfusion (Fig. 4) . External efficiency was decreased to 14±9% in group 1 and to 23±7% in group 2. EMD 60263 improved the external efficiency index to control levels (109±21%), enoximon to 57±13% of control. The contractile efficiency – the reciprocal of the slope of the MVO2–PVA relation – was significantly depressed in both groups, to 71±7% in the Ca2+-sensitizer group and to 65±9% in the enoximon group. After administration of EMD 60263, EFcont was non-significantly increased to 84±11% of preischemic value and after enoximon, EFcont remained almost unchanged compared with reperfusion (71±12% of control value). MVO2 for the unloaded contraction increased non-significantly by 15±6% in group 1 and 23±8% in group 2.



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 4. Effects of 20 min global no-flow ischemia and administration of inotropic agents ({square}, EMD 60263; {blacksquare}, enoximon) on external efficiency (EFex; left panel) and contractile efficiency (EFcont; right panel). The bars represent mean values±SD, P<0.05, *control vs. reperfusion,°reperfusion vs. agent.

 

    4. Discussion
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
The relationship between ventricular function and myocardial oxygen consumption was investigated in stunned myocardium and after application of two different inotropic agents. The major findings were: (1) the calcium-sensitizer EMD 60263 and the phosphodiesterase (PDE) III inhibitor enoximon, recruited an inotropic reserve; (2) myocardial efficiency indices remained almost depressed after application of enoximon, whereas EMD 60263 improved both efficiency indices.

Depressed contractile function in viable myocardium at almost restored coronary flow, i.e. oxygen and energy supply, are major characteristics of stunned myocardium [1,2]. Possible causes underlying this phenomenon are free radical damaging of membranes and enzymes [9], calcium overload during ischemia and early reperfusion with activation of proteases and alteration of intracellular calcium-cycling [12]. In accordance with the literature, our data show a significant reduction of all functional parameters.

The relationship between ventricular function and myocardial oxygen consumption was investigated via the external efficiency. This term stresses the ratio between external work, i.e. stroke work (stroke volume times developed pressure), and the total energy demand, i.e. total myocardial oxygen consumption. In the present study, external efficiency was drastically reduced in both postischemic groups. Even after 30 min reperfusion, there was no substantial recovery. These results are in accordance with data from the literature; however, the decline in our data seems to be more pronounced, but the different types of ischemia (no-flow or low-flow ischemia), temperature and species might explain the difference with other studies.

Contractile efficiency was calculated by the relationship between MVO2 and the pressure–volume area according to Suga and coworkers [13]. In contrast to the external efficiency, the MVO2–PVA concept allows partitioning of the MVO2 in one fraction that is needed for contraction and another that is non-work related, i.e. the unloaded contraction. This separation clearly showed a decrease of contractile efficiency in stunned myocardium and, in turn, an inefficient electromechanical coupling. The principal cause of myocardial stunning and loss of myocardial efficiency is not fully understood. Changes of energy requirements for calcium handling could increase myocardial oxygen consumption. However, there is evidence for a loss of Ca2+-sensitivity of the myofilaments in stunned compared with normal myocardium as a major underlying mechanism. Based on experiments with isolated ferret hearts this mechanism was first proposed in 1987 by Kusuoka et al. [23]. Moreover, other groups found a decrease in the Ca2+-sensitivity of isometric tension in skinned fibers from stunned pig myocardium [24] and in the intact ventricular muscle [12]. This alteration might implicate the increased energy demand of the myofilaments to generate force.

The inefficiency of the myocardium has also been attributed to ischemia-induced injury such as uncoupling of oxidative phosphorylation [14]. However, no data exist confirming mitochondrial uncoupling [15]. In the present study, MVO2 for the unloaded contraction did not differ significantly between normal and stunned myocardium. MVO2 for the unloaded contraction, which contains the fraction for basal metabolism and another for excitation–contraction coupling, increases with increasing contractile state and decreases with decreasing contractile state [16]. Therefore, our results suggest that the maintained MVO2 for the unloaded contraction is inadequately high in relation to the decreased postischemic contractile state. In a previous study of our group, basal MVO2 after KCl arrest was assessed in a similar protocol. Basal MVO2 was not elevated in postischemic hearts, suggesting that the fraction of MVO2 attributable to excitation–contraction is disproportionately high in stunned myocardium [17]. Therefore the excess oxygen utilization at a state of reduced contractile function cannot be explained by an increased metabolic need for postischemic repair mechanisms taking place during this condition [8] and indeed, calcium transport mechanisms of cell membranes and the sarcoplasmic reticulum are impaired in stunned myocardium [10,11].

Inotropic support is often necessary for the long-lasting myocardial dysfunction after brief periods of ischemia, i.e. perioperatively in cardiac surgery patients after ischemic arrest. Most of the clinically used inotropic drugs, such as {alpha}- and ß-adrenergic agonists, and PDE III-inhibitors, act by increasing Ca2+-loading of the cytosol and sarcoplasmic reticulum, leading to an increase of the Ca2+ transients [4]. But this is associated with a disproportionate increase in myocardial oxygen requirement [18]. A number of new cardiotonic drugs do not act through increased cytosolic calcium transients, but affect also Ca2+-sensitization (i.e. shift in the pCa–force relation) in both skinned and intact cardiac muscle preparations [5]. Thiadiazinone derivatives vary widely in their ability to sensitize the myofilaments towards Ca2+ and to increase cellular cyclic AMP levels via their PDE III inhibitory action; the (+)-enantiomer EMD 60263 has been described as the first Ca2+-sensitizer devoid of PDE III inhibitory activity [19]. The concentration (IC50) of EMD 60263 required to reach half-maximal PDE III inhibition activity is reported to be >30 µM [20], a concentration clearly higher than the one used in our study.

The inotropic actions of the Ca2+-sensitizer EMD 60263 and the PDE III inhibitor enoximon were tested in a constant afterload preparation to eliminate any afterload effects. In the isolated rabbit heart preparation, postischemic ventricular dysfunction was significantly improved with both agents, reaching almost preischemic control levels with the selected drug concentrations. These findings were not unexpected and are in accordance with the notion that ventricular function can be improved by recruiting an inotropic reserve [20]. An in vivo study in pigs demonstrated that EMD 60263 increased systolic segment shortening of stunned and nonstunned myocardium, the effect being more pronounced in stunned than in nonstunned myocardium [21]. According to the concept of loss of Ca2+-responsiveness of the myofilaments as a major cause of stunning, these data and our results demonstrate that Ca2+-sensitizers are very effective inotropic agents in this particular setting of stunned myocardium. Interestingly, only enoximon increased heart rate significantly, but no arrhythmogenic effects were found in the presence of either agent in the stunned myocardium.

The external efficiency was substantially improved to control levels with EMD 60263 (109%), whereas EFex remained depressed with enoximon (57%). After administration of both drugs, contractile efficiency was slightly increased with EMD 60263 and remained unchanged with enoximon. With respect to the better improvement of myocardial efficiency with the Ca2+-sensitizer compared with the PDE III inhibitor, the present data also underline the reduced Ca2+-responsiveness as a major cause for energy wastage in the stunned myocardium. Therefore, Ca2+-sensitization also improves the energetic balance, whereas other inotropic agents do not. Another advantage of Ca2+-sensitization compared with phosphodiesterase inhibition, with its known vasodilatory effects, might be that no systemic vasodilatory properties were seen. This was shown in an in vivo study in pigs [21]. However, despite the quite interesting perspectives of Ca2+-sensitization in the management of postoperative heart failure, there are only a few clinical trials with the agent Levosimendan. In a clinical study, this Ca2+-sensitizer, which also has phosphodiesterase-inhibiting properties, showed an enhancement of cardiac performance after cardiopulmonary bypass in humans [25].

The MVO2–PVA relationship has been shown to be more sensitive in the settings of ischemia [22] compared with other efficiency assessments. The absence of complete recovery of contractile efficiency, even after Ca2+-sensitization, indicates that in stunned myocardium energy utilization is disturbed and can scarcely be improved.


    5. Conclusion
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
In our model of myocardial stunning, the imbalance of oxygen consumption to decreased ventricular function, as demonstrated by the decline of efficiency indices, shows the energetic inefficiency of the myocardium. Ca2+-sensitization and PDE III inhibition both can recruit an inotropic reserve. Because Ca2+-sensitization seems to be more favorable in terms of myocardial efficiency, we conclude that Ca2+-desensitization is an attribute of the phenomenon of myocardial stunning. The maintained MVO2 for the unloaded contraction in stunned myocardium and its moderate change after Ca2+-sensitization also indicate that disturbances in excitation–contraction coupling contribute to the inefficiency. Taken together, concerning myocardial efficiency the Ca2+-sensitizer seems to exert more beneficial effects in postischemic inotropic stimulation.


    Footnotes
 
Presented at the 13th Annual Meeting of the European Association for Cardio-thoracic Surgery, Glasgow, Scotland, UK, September 5–8, 1999.


    Appendix A. Conference discussion
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 
Dr L. von Segesser (Lausanne, Switzerland): You are working in an isolated rabbit model, and you can therefore not appreciate what happens to the peripheral resistance when you modify the heart function.

Dr Sunderdiek: No, we can't do it in this model.

Dr von Segesser: But your drugs would; they would also act on the muscles of the vessels?

Dr Sunderdiek: Yes, they certainly would, and there are a couple of studies using the calcium sensitizer in pigs by the group of Verdow from Rotterdam, and they showed that the systemic blood pressure was well maintained.

Dr J. Svennevig (Oslo, Norway): Would you just very briefly indicate possible clinical implications.

Dr Sunderdiek: A clinical implication would be, for instance, a state of low cardiac output postoperatively after an operation with myocardial ischemia, i.e. coronary bypass surgery. Then we will have the need for inotropic intervention, and the calcium sensitizer might be a good alternative to improve myocardial function postoperatively.

Dr von Segesser: But then you would increase afterload with this drug, whereas with enoximon you would decrease afterload. Am I right?

Dr Sunderdiek: The data do not show an influence of the calcium sensitizer EMD 60263 on systemic blood pressure. So probably with an increase of cardiac output we might have at least an indirect increase of afterload conditions. But so far, at the moment there are not so many in vivo measurements to show reliable data of afterload changes.

Dr C. Stamm (Boston, MA, USA): PDE III inhibitors, just like catecholamines, actually desensitize contractile proteins to calcium via PKA and troponin I. With a pure, 100% calcium-sensitizing agent one would expect an impairment of relaxation associated with the improvement of contractility. Did you observe this?

Dr Sunderdiek: Yes, we did some further studies, because the presented data showed only dP/dtmin as a parameter of early relaxation with no real alterations. In further studies we also measured the relation of {tau} and the end-diastolic pressure–volume relation, and both parameters showed a decrease of diastolic function after administration of the calcium sensitizer.

Dr Stamm: Most of those calcium-sensitizing agents have some PDE III-inhibiting properties. Do you know to which extent this is true for the EMD that you used?

Dr Sunderdiek: We got some data from the group of Dr Ravens from Essen in Germany, and they said that in this dosage of 10 µM, the extent for phosphodiesterase inhibition of this agent would be very low. So, I can't tell you any exact percentage, but I would guess that the agents property of phosphodiesterase inhibition would be lower than 10% of the total inotropic effect.


    References
 Top
 Abstract
 1. Introduction
 2. Materials and methods
 3. Results
 4. Discussion
 5. Conclusion
 Appendix A. Conference...
 References
 

  1. Braunwald E., Kloner R.A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1992;66:1146-1149.
  2. Laxter S.B., Becker L.C., Ambrosio G., Jacobus W.E. Reduced aerobic metabolic efficiency in globally stunned myocardium. J Mol Cell Cardiol 1989;21:419-426.[Medline]
  3. Schipke J.D., Korbmacher B., Dorszewski A., Selcan G., Sunderdiek U., Arnold G. Hemodynamic and energetic properties of stunned myocardium in rabbit hearts. Heart 1996;75:55-61.[Abstract/Free Full Text]
  4. Reiter C.A. Calcium mobilization and cardiac inotropic mechanisms. Pharmacol Rev 1988;40:189-217.[Medline]
  5. Lee J.A., Allen D.G. Altering the strength of the heart: basic mechanisms. In: Lee J.A., Allen D.G., eds. Modulation of cardiac calcium sensitivity. New York: Oxford University Press, 1993:197-266.
  6. Schulz R., Ehring T., Heusch G. Stunned myocardium: inotropic reserve and pharmacological attenuation. Bas Res Cardiol 1995;90:967-975.
  7. Goerge G., Papageorgiou I., Lerch R. Epinephrine-stimulated contractile and metabolic reserve in postischemic rat myocardium. Bas Res Cardiol 1990;85:595-605.[Medline]
  8. Britz M., Sunderdiek U., Schipke J.D. Easydat: a computer program for data acquisition and processing (abstract). Pflügers Arch 1992;420(Suppl I):R140.
  9. Bolli R. Mechanism of myocardial stunning. Circulation 1990;82:723-738.[Abstract/Free Full Text]
  10. Kusuoka H., Koretsune Y., Chacko V.P., Weisfeldt M.L., Marban E. Excitation–contraction coupling in postischemic myocardium. Does failure of activator Ca2+ transients underlie stunning?. Circ Res 1990;66:1268-1276.[Abstract/Free Full Text]
  11. Krause S.M., Jacobus W.E., Becker L.C. Alterations in cardiac sarcoplasmatic reticulum calcium transport in the postischemic stunned myocardium. Circ Res 1989;65:526-530.[Abstract/Free Full Text]
  12. Gao W.D., Atar D., Backx P.H., Marban E. Relationship between intracellular calcium and contractile force in stunned myocardium: direct evidence for decreased myofilament Ca2+ responsiveness and altered diastolic function in intact ventricular muscle. Circ Res 1995;76:1036-1048.[Abstract/Free Full Text]
  13. Suga H. Ventricular energetics. Physiol Rev 1990;70:247-277.[Free Full Text]
  14. Liedtke A.J., De Maison L., Eggleston A.M., Cohen L.M., Nellis S.A. Changes in substrate metabolism and effects of excess fatty acid in reperfused myocardium. Circ Res 1988;62:535-542.[Abstract/Free Full Text]
  15. Burkhoff D. Myocardial energetics and the postischemic heart. Ann Thorac Surg 1990;49:525-527.[Medline]
  16. Suga H., Goto Y., Yasamura Y., Nozawana T., Futaki S., Tanaka N., Uenishi M. Oxygen consumption of dog heart under decreased coronary perfusion and propranolol. Am J Physiol 1988;254:H292-H203.
  17. Schipke J., Korbmacher B., Schwanke U., Frehen D., Schmidt T., Arnold G. Basal metabolism does not account for high O2 consumption in stunned myocardium. Am J Physiol 1998;H274:H743-746.
  18. Suga H., Hisano R., Goto Y., Yamada O., Igarashi Y. Effects of positive inotropic agents on the relation between oxygen consumption and systolic pressure–volume relation in canine left ventricle. Circ Res 1983;53:306-318.[Abstract/Free Full Text]
  19. Ravens U., Flüss M., Amos G.J., Himmel H.M., Wettwer E., Lues I. The new Ca2+-sensitizing agent EMD 60263 and its enantiomer EMD 60264: inotropic and electrophysiological actions. Naunyn-Schmiedebergs Arch Pharmacol 1993;348(Suppl):85.
  20. Bezstarosti K., Soei L.K., Krams R., Ten Cate F.J., Verdouw P.D., Lamers J.M. The effect of a thiadiazinone derived Ca2+-sensitizer on the responsiveness of Mg2+-ATPase to Ca2+ in myofibrils isolated from stunned and nonstunned porcine and human myocardium. Biochem Pharmacol 1996;51:1211-1220.[Medline]
  21. Soie L.K., Sassan L.M.A., Fan D.S., Van Veen T., Krams R., Verdouw P.D. Myofibrillar Ca2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation 1994;90:959-969.[Abstract/Free Full Text]
  22. Glower D.D., Spratt J.A., Kabas S., Davies J.W., Rabkin J.S. Quantification of regional myocardial dysfunction after acute ischemic injury. Am J Physiol 1988;255:H85-H93.
  23. Kusuoka H., Porterfield J.K., Weisman H.F., Weisfeldt M.L., Marban E. Pathophysiology and pathogenesis of stunned myocardium: depressed Ca2+ activation of contraction as a consequence or reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest 1987;79:950-961.
  24. McDonald K.S., Mammen P.P.A., Strang K.T., Moss R.L., Miller W.P. Isometric and dynamic contractile properties of porcine skinned cardiac myocytes after stunning. Circ Res 1995;77:964-972.[Abstract/Free Full Text]
  25. Nijhawan N., Nicolosi A.C., Montgomery M.W., Aggarwal A., Pagel P.S., Warltier D.C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-228.[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Bernhard Korbmacher
Emmeran Gams
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sunderdiek, U.
Right arrow Articles by Schipke, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sunderdiek, U.
Right arrow Articles by Schipke, J. D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS